DPI-386 INTRANASAL SCOPOLAMINE


Associated tags: Scopolamine, Absorption, Motion, Pharmaceutical industry, Motion sickness, Astronaut, Central nervous system, Dietary supplement, Mars, US Foods, New Drug Application, International Space Station, Vomiting, Incidence, Nausea, Transport, NASA, Contribution, Knowledge, National Aeronautics and Space Act

Defender Pharmaceuticals Announces Collaboration with NASA on Two Phase 2 Clinical Trials Investigating DPI-386’s Ability to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Retrieved on: 
Tuesday, October 24, 2023
Astronaut, Knowledge, Comment, Johnson Space Center, Polaris Dawn, Health, Motion sickness, Inspiration4, Scientific research on the International Space Station, Human, Orion, SpaceX, Doctor of Philosophy, Research, PVT, Spaceflight, National Aeronautics and Space Act, Contribution, International Space Station, NASA, Motion, Pharmaceutical industry, Dietary supplement, Mars

First study evaluates DPI-386 alone and in combination with sensory augmentation to effectively mitigate motion sickness and improve task performance, in comparison to placebo.

Key Points: 
  • First study evaluates DPI-386 alone and in combination with sensory augmentation to effectively mitigate motion sickness and improve task performance, in comparison to placebo.
  • Second study evaluates the feasibility and efficacy of administering DPI-386 in operational field settings, with both astronaut and ground-control subjects, when exposed to provocative motion.
  • Both trials are being led by primary investigator Scott J Wood, PhD of NASA, and Neuroscience Laboratory Principal Investigator.
  • As the only clinical pharmacologist at NASA, Dr. Putcha was responsible for directing and conducting the research and development program for optimizing pharmacotherapeutics in space.

Defender Pharmaceuticals Phase 3 Motion Sickness Trial Results Selected for Presentation at 2023 Military Health System Research Symposium (MHSRS)

Retrieved on: 
Thursday, August 10, 2023
US Foods, Central nervous system, New Drug Application, Motion sickness, Absorption, Scopolamine, Vomiting, Incidence, Motion, Nausea, Transport, Safety, Pharmaceutical industry

ST. LOUIS, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Defender Pharmaceuticals, Inc. (the “Company” or “Defender”), a privately held life sciences company based in St. Louis, today announced that the previously reported, positive results from its Phase 3 clinical trial with DPI-386 Nasal Gel for prevention of nausea and vomiting induced by motion in adults has been selected for presentation at the upcoming 2023 Military Health System Research Symposium (MHSRS) to be held August 14 -17, 2023 in Kissimmee, FL.

Key Points: 
  • ST. LOUIS, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Defender Pharmaceuticals, Inc. (the “Company” or “Defender”), a privately held life sciences company based in St. Louis, today announced that the previously reported, positive results from its Phase 3 clinical trial with DPI-386 Nasal Gel for prevention of nausea and vomiting induced by motion in adults has been selected for presentation at the upcoming 2023 Military Health System Research Symposium (MHSRS) to be held August 14 -17, 2023 in Kissimmee, FL.
  • “The selection of our Phase 3 clinical trial results for presentation at this premiere event underscores both the strength of the data and the heavy impact that motion sickness has on the ability to ensure effective military operations,” said Barry I. Feinberg, M.D., President & CEO of Defender Pharmaceuticals.
  • Abstract title: Efficacy of Intranasal Scopolamine HBr (INSCOP, DPI-386) for the prevention of vomiting or the need for rescue medication associated with motion.
  • The poster will be available on the Company’s website at https://defenderpharma.com/ shortly after the event.